Fasting plasma lactate as a possible early clinical marker for metabolic disease risk
Elevated fasting plasma lactate concentrations are evident in individuals with metabolic diseases. However, it has yet to be determined if these associations exist in a young, healthy population as a possible early marker for metabolic disease risk. The purpose of this study was to determine if indi...
Gespeichert in:
| Veröffentlicht in: | Diabetes & metabolic syndrome clinical research & reviews 2024-02, Vol.18 (2), p.102955-102955, Article 102955 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 102955 |
|---|---|
| container_issue | 2 |
| container_start_page | 102955 |
| container_title | Diabetes & metabolic syndrome clinical research & reviews |
| container_volume | 18 |
| creator | Broskey, Nicholas T. Pories, Walter J. DeMaria, Eric J. Jones, Terry E. Tanner, Charles J. Zheng, Donghai Krassovskaia, Polina M. Mitchell, Lindsay A. Matarese, Laura E. O'Brien, Kevin F. Cortright, Ronald N. Dohm, G. Lynis Houmard, Joseph A. |
| description | Elevated fasting plasma lactate concentrations are evident in individuals with metabolic diseases. However, it has yet to be determined if these associations exist in a young, healthy population as a possible early marker for metabolic disease risk. The purpose of this study was to determine if indices of the metabolic syndrome are related to plasma lactate concentrations in this population.
Fifty (29 ± 7 yr) men (n = 19) and women (n = 31) classified as overweight (26.4 ± 1.8 kg/m2) participated in this observational study. Blood pressure and blood metabolites were measured after an overnight fast. Lactate was also measured before and after a three-day eucaloric high-fat (70 %) diet. The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated as a measure of insulin resistance. Visceral adipose tissue mass was determined via dual X-ray absorptiometry.
Triglycerides (r = 0.55, p= |
| doi_str_mv | 10.1016/j.dsx.2024.102955 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2922453242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S187140212400016X</els_id><sourcerecordid>2922453242</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-a9d72b7b0e8bb6c4f3c1182ed5ab7f174cc5f3cc015a4581344ffc6a0bce11f23</originalsourceid><addsrcrecordid>eNp9kElPwzAQhSMEYin8AC7IRy4pXptEnBBik5C4wNkaTybIrdMUO0Xw73EpcOQ0i9680fuK4lTwqeBidjGftuljKrnUeZaNMTvFoairuuRK6d3vXpSaS3FQHKU059yYRjb7xYGqleCVmh0WL7eQRr98ZasAqQcWAEcYiUFiwFZDSt4FYgQxfDIMfukRAushLiiyboispxHcEDyy1ieCRCz6tDgu9joIiU5-6iT_uXm-vi8fn-4erq8eS1RGjSU0bSVd5TjVzs1QdwqFqCW1BlzViUojmrxDLgxoUwulddfhDLhDEqKTalKcb31XcXhbUxpt7xNSCLCkYZ2sbKTURkm9kYqtFGNOFamzq-hzkE8ruN3QtHObadoNTbulmW_OfuzXrqf27-IXXxZcbgWUQ757ijahpyVS6yPhaNvB_2P_BWWAhd8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2922453242</pqid></control><display><type>article</type><title>Fasting plasma lactate as a possible early clinical marker for metabolic disease risk</title><source>Access via ScienceDirect (Elsevier)</source><creator>Broskey, Nicholas T. ; Pories, Walter J. ; DeMaria, Eric J. ; Jones, Terry E. ; Tanner, Charles J. ; Zheng, Donghai ; Krassovskaia, Polina M. ; Mitchell, Lindsay A. ; Matarese, Laura E. ; O'Brien, Kevin F. ; Cortright, Ronald N. ; Dohm, G. Lynis ; Houmard, Joseph A.</creator><creatorcontrib>Broskey, Nicholas T. ; Pories, Walter J. ; DeMaria, Eric J. ; Jones, Terry E. ; Tanner, Charles J. ; Zheng, Donghai ; Krassovskaia, Polina M. ; Mitchell, Lindsay A. ; Matarese, Laura E. ; O'Brien, Kevin F. ; Cortright, Ronald N. ; Dohm, G. Lynis ; Houmard, Joseph A.</creatorcontrib><description>Elevated fasting plasma lactate concentrations are evident in individuals with metabolic diseases. However, it has yet to be determined if these associations exist in a young, healthy population as a possible early marker for metabolic disease risk. The purpose of this study was to determine if indices of the metabolic syndrome are related to plasma lactate concentrations in this population.
Fifty (29 ± 7 yr) men (n = 19) and women (n = 31) classified as overweight (26.4 ± 1.8 kg/m2) participated in this observational study. Blood pressure and blood metabolites were measured after an overnight fast. Lactate was also measured before and after a three-day eucaloric high-fat (70 %) diet. The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated as a measure of insulin resistance. Visceral adipose tissue mass was determined via dual X-ray absorptiometry.
Triglycerides (r = 0.55, p=<0.0001), HOMA-IR (r = 0.53, p=<0.0001), and systolic and diastolic (both, r = 0.36, p = 0.01) blood pressures associated with fasting plasma lactate. No differences in visceral adipose tissue existed between the sexes (p = 0.41); however, the relationship between visceral adipose tissue and lactate existed only in females (r = 0.59, p = 0.02) but not in males (p = 0.53). Fasting lactate and HOMA-IR increased in males (p = 0.01 and p = 0.02, respectively), but not females, following a three-day high-fat diet.
Indices of the metabolic syndrome associated with fasting plasma lactates in young relatively healthy individuals. Fasting lactate also increased in a sex-specific manner after a three-day high fat diet. Thus, lactate could become a clinical marker for metabolic disease risk.
•Individuals with metabolic disease have elevated fasting plasma lactate.•In healthy subjects, factors of the metabolic syndrome associated with lactate.•Fasting lactate is stable over three separate visits but increased after a three-day high-fat diet.•Fasting lactate may be used as an early biomarker to identify individuals at risk for metabolic disease.</description><identifier>ISSN: 1871-4021</identifier><identifier>EISSN: 1878-0334</identifier><identifier>DOI: 10.1016/j.dsx.2024.102955</identifier><identifier>PMID: 38310736</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Clinical marker ; Diabetes risk ; Insulin resistance ; Lactate ; Metabolic syndrome</subject><ispartof>Diabetes & metabolic syndrome clinical research & reviews, 2024-02, Vol.18 (2), p.102955-102955, Article 102955</ispartof><rights>2024 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC)</rights><rights>Copyright © 2024 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-a9d72b7b0e8bb6c4f3c1182ed5ab7f174cc5f3cc015a4581344ffc6a0bce11f23</citedby><cites>FETCH-LOGICAL-c353t-a9d72b7b0e8bb6c4f3c1182ed5ab7f174cc5f3cc015a4581344ffc6a0bce11f23</cites><orcidid>0000-0002-1197-5116</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.dsx.2024.102955$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38310736$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Broskey, Nicholas T.</creatorcontrib><creatorcontrib>Pories, Walter J.</creatorcontrib><creatorcontrib>DeMaria, Eric J.</creatorcontrib><creatorcontrib>Jones, Terry E.</creatorcontrib><creatorcontrib>Tanner, Charles J.</creatorcontrib><creatorcontrib>Zheng, Donghai</creatorcontrib><creatorcontrib>Krassovskaia, Polina M.</creatorcontrib><creatorcontrib>Mitchell, Lindsay A.</creatorcontrib><creatorcontrib>Matarese, Laura E.</creatorcontrib><creatorcontrib>O'Brien, Kevin F.</creatorcontrib><creatorcontrib>Cortright, Ronald N.</creatorcontrib><creatorcontrib>Dohm, G. Lynis</creatorcontrib><creatorcontrib>Houmard, Joseph A.</creatorcontrib><title>Fasting plasma lactate as a possible early clinical marker for metabolic disease risk</title><title>Diabetes & metabolic syndrome clinical research & reviews</title><addtitle>Diabetes Metab Syndr</addtitle><description>Elevated fasting plasma lactate concentrations are evident in individuals with metabolic diseases. However, it has yet to be determined if these associations exist in a young, healthy population as a possible early marker for metabolic disease risk. The purpose of this study was to determine if indices of the metabolic syndrome are related to plasma lactate concentrations in this population.
Fifty (29 ± 7 yr) men (n = 19) and women (n = 31) classified as overweight (26.4 ± 1.8 kg/m2) participated in this observational study. Blood pressure and blood metabolites were measured after an overnight fast. Lactate was also measured before and after a three-day eucaloric high-fat (70 %) diet. The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated as a measure of insulin resistance. Visceral adipose tissue mass was determined via dual X-ray absorptiometry.
Triglycerides (r = 0.55, p=<0.0001), HOMA-IR (r = 0.53, p=<0.0001), and systolic and diastolic (both, r = 0.36, p = 0.01) blood pressures associated with fasting plasma lactate. No differences in visceral adipose tissue existed between the sexes (p = 0.41); however, the relationship between visceral adipose tissue and lactate existed only in females (r = 0.59, p = 0.02) but not in males (p = 0.53). Fasting lactate and HOMA-IR increased in males (p = 0.01 and p = 0.02, respectively), but not females, following a three-day high-fat diet.
Indices of the metabolic syndrome associated with fasting plasma lactates in young relatively healthy individuals. Fasting lactate also increased in a sex-specific manner after a three-day high fat diet. Thus, lactate could become a clinical marker for metabolic disease risk.
•Individuals with metabolic disease have elevated fasting plasma lactate.•In healthy subjects, factors of the metabolic syndrome associated with lactate.•Fasting lactate is stable over three separate visits but increased after a three-day high-fat diet.•Fasting lactate may be used as an early biomarker to identify individuals at risk for metabolic disease.</description><subject>Clinical marker</subject><subject>Diabetes risk</subject><subject>Insulin resistance</subject><subject>Lactate</subject><subject>Metabolic syndrome</subject><issn>1871-4021</issn><issn>1878-0334</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kElPwzAQhSMEYin8AC7IRy4pXptEnBBik5C4wNkaTybIrdMUO0Xw73EpcOQ0i9680fuK4lTwqeBidjGftuljKrnUeZaNMTvFoairuuRK6d3vXpSaS3FQHKU059yYRjb7xYGqleCVmh0WL7eQRr98ZasAqQcWAEcYiUFiwFZDSt4FYgQxfDIMfukRAushLiiyboispxHcEDyy1ieCRCz6tDgu9joIiU5-6iT_uXm-vi8fn-4erq8eS1RGjSU0bSVd5TjVzs1QdwqFqCW1BlzViUojmrxDLgxoUwulddfhDLhDEqKTalKcb31XcXhbUxpt7xNSCLCkYZ2sbKTURkm9kYqtFGNOFamzq-hzkE8ruN3QtHObadoNTbulmW_OfuzXrqf27-IXXxZcbgWUQ757ijahpyVS6yPhaNvB_2P_BWWAhd8</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>Broskey, Nicholas T.</creator><creator>Pories, Walter J.</creator><creator>DeMaria, Eric J.</creator><creator>Jones, Terry E.</creator><creator>Tanner, Charles J.</creator><creator>Zheng, Donghai</creator><creator>Krassovskaia, Polina M.</creator><creator>Mitchell, Lindsay A.</creator><creator>Matarese, Laura E.</creator><creator>O'Brien, Kevin F.</creator><creator>Cortright, Ronald N.</creator><creator>Dohm, G. Lynis</creator><creator>Houmard, Joseph A.</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1197-5116</orcidid></search><sort><creationdate>202402</creationdate><title>Fasting plasma lactate as a possible early clinical marker for metabolic disease risk</title><author>Broskey, Nicholas T. ; Pories, Walter J. ; DeMaria, Eric J. ; Jones, Terry E. ; Tanner, Charles J. ; Zheng, Donghai ; Krassovskaia, Polina M. ; Mitchell, Lindsay A. ; Matarese, Laura E. ; O'Brien, Kevin F. ; Cortright, Ronald N. ; Dohm, G. Lynis ; Houmard, Joseph A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-a9d72b7b0e8bb6c4f3c1182ed5ab7f174cc5f3cc015a4581344ffc6a0bce11f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Clinical marker</topic><topic>Diabetes risk</topic><topic>Insulin resistance</topic><topic>Lactate</topic><topic>Metabolic syndrome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Broskey, Nicholas T.</creatorcontrib><creatorcontrib>Pories, Walter J.</creatorcontrib><creatorcontrib>DeMaria, Eric J.</creatorcontrib><creatorcontrib>Jones, Terry E.</creatorcontrib><creatorcontrib>Tanner, Charles J.</creatorcontrib><creatorcontrib>Zheng, Donghai</creatorcontrib><creatorcontrib>Krassovskaia, Polina M.</creatorcontrib><creatorcontrib>Mitchell, Lindsay A.</creatorcontrib><creatorcontrib>Matarese, Laura E.</creatorcontrib><creatorcontrib>O'Brien, Kevin F.</creatorcontrib><creatorcontrib>Cortright, Ronald N.</creatorcontrib><creatorcontrib>Dohm, G. Lynis</creatorcontrib><creatorcontrib>Houmard, Joseph A.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes & metabolic syndrome clinical research & reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Broskey, Nicholas T.</au><au>Pories, Walter J.</au><au>DeMaria, Eric J.</au><au>Jones, Terry E.</au><au>Tanner, Charles J.</au><au>Zheng, Donghai</au><au>Krassovskaia, Polina M.</au><au>Mitchell, Lindsay A.</au><au>Matarese, Laura E.</au><au>O'Brien, Kevin F.</au><au>Cortright, Ronald N.</au><au>Dohm, G. Lynis</au><au>Houmard, Joseph A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fasting plasma lactate as a possible early clinical marker for metabolic disease risk</atitle><jtitle>Diabetes & metabolic syndrome clinical research & reviews</jtitle><addtitle>Diabetes Metab Syndr</addtitle><date>2024-02</date><risdate>2024</risdate><volume>18</volume><issue>2</issue><spage>102955</spage><epage>102955</epage><pages>102955-102955</pages><artnum>102955</artnum><issn>1871-4021</issn><eissn>1878-0334</eissn><abstract>Elevated fasting plasma lactate concentrations are evident in individuals with metabolic diseases. However, it has yet to be determined if these associations exist in a young, healthy population as a possible early marker for metabolic disease risk. The purpose of this study was to determine if indices of the metabolic syndrome are related to plasma lactate concentrations in this population.
Fifty (29 ± 7 yr) men (n = 19) and women (n = 31) classified as overweight (26.4 ± 1.8 kg/m2) participated in this observational study. Blood pressure and blood metabolites were measured after an overnight fast. Lactate was also measured before and after a three-day eucaloric high-fat (70 %) diet. The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated as a measure of insulin resistance. Visceral adipose tissue mass was determined via dual X-ray absorptiometry.
Triglycerides (r = 0.55, p=<0.0001), HOMA-IR (r = 0.53, p=<0.0001), and systolic and diastolic (both, r = 0.36, p = 0.01) blood pressures associated with fasting plasma lactate. No differences in visceral adipose tissue existed between the sexes (p = 0.41); however, the relationship between visceral adipose tissue and lactate existed only in females (r = 0.59, p = 0.02) but not in males (p = 0.53). Fasting lactate and HOMA-IR increased in males (p = 0.01 and p = 0.02, respectively), but not females, following a three-day high-fat diet.
Indices of the metabolic syndrome associated with fasting plasma lactates in young relatively healthy individuals. Fasting lactate also increased in a sex-specific manner after a three-day high fat diet. Thus, lactate could become a clinical marker for metabolic disease risk.
•Individuals with metabolic disease have elevated fasting plasma lactate.•In healthy subjects, factors of the metabolic syndrome associated with lactate.•Fasting lactate is stable over three separate visits but increased after a three-day high-fat diet.•Fasting lactate may be used as an early biomarker to identify individuals at risk for metabolic disease.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>38310736</pmid><doi>10.1016/j.dsx.2024.102955</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-1197-5116</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1871-4021 |
| ispartof | Diabetes & metabolic syndrome clinical research & reviews, 2024-02, Vol.18 (2), p.102955-102955, Article 102955 |
| issn | 1871-4021 1878-0334 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2922453242 |
| source | Access via ScienceDirect (Elsevier) |
| subjects | Clinical marker Diabetes risk Insulin resistance Lactate Metabolic syndrome |
| title | Fasting plasma lactate as a possible early clinical marker for metabolic disease risk |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T04%3A02%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fasting%20plasma%20lactate%20as%20a%20possible%20early%20clinical%20marker%20for%20metabolic%20disease%20risk&rft.jtitle=Diabetes%20&%20metabolic%20syndrome%20clinical%20research%20&%20reviews&rft.au=Broskey,%20Nicholas%20T.&rft.date=2024-02&rft.volume=18&rft.issue=2&rft.spage=102955&rft.epage=102955&rft.pages=102955-102955&rft.artnum=102955&rft.issn=1871-4021&rft.eissn=1878-0334&rft_id=info:doi/10.1016/j.dsx.2024.102955&rft_dat=%3Cproquest_cross%3E2922453242%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2922453242&rft_id=info:pmid/38310736&rft_els_id=S187140212400016X&rfr_iscdi=true |